CN106619520B - 一种右兰索拉唑钠的干混悬剂及其制备方法 - Google Patents
一种右兰索拉唑钠的干混悬剂及其制备方法 Download PDFInfo
- Publication number
- CN106619520B CN106619520B CN201611241574.3A CN201611241574A CN106619520B CN 106619520 B CN106619520 B CN 106619520B CN 201611241574 A CN201611241574 A CN 201611241574A CN 106619520 B CN106619520 B CN 106619520B
- Authority
- CN
- China
- Prior art keywords
- sodium
- parts
- lansoprazole
- release
- novel crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611241574.3A CN106619520B (zh) | 2016-12-29 | 2016-12-29 | 一种右兰索拉唑钠的干混悬剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611241574.3A CN106619520B (zh) | 2016-12-29 | 2016-12-29 | 一种右兰索拉唑钠的干混悬剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106619520A CN106619520A (zh) | 2017-05-10 |
CN106619520B true CN106619520B (zh) | 2019-08-06 |
Family
ID=58835399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611241574.3A Active CN106619520B (zh) | 2016-12-29 | 2016-12-29 | 一种右兰索拉唑钠的干混悬剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106619520B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107456444B (zh) * | 2017-08-14 | 2021-07-02 | 南京百思福医药科技有限公司 | 一种莫沙必利的缓释干混悬剂及其制备方法 |
CN107802613B (zh) * | 2017-11-13 | 2020-01-31 | 郑州大学 | 一种掩味肠道速释型替米考星微纳米干混悬剂及其制备方法 |
AU2020377451A1 (en) * | 2019-11-04 | 2022-05-26 | Cinclus Pharma Holding AB | Oral formulation of X842 |
CN116115563B (zh) * | 2023-03-30 | 2023-08-29 | 石家庄四药有限公司 | 一种氟比洛芬混悬注射液及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101137371A (zh) * | 2005-01-14 | 2008-03-05 | 克卡制药新梅斯托股份公司 | 制备兰索拉唑的方法 |
CN101977909A (zh) * | 2008-03-18 | 2011-02-16 | 雷迪博士实验室有限公司 | 右兰索拉唑方法和多晶型物 |
CN102119927A (zh) * | 2010-01-11 | 2011-07-13 | 石药集团中奇制药技术(石家庄)有限公司 | 一种质子泵抑制剂的肠溶微丸制剂及其制备方法 |
CN103565770A (zh) * | 2012-07-31 | 2014-02-12 | 北京阜康仁生物制药科技有限公司 | 一种右兰索拉唑肠溶缓控释微丸片 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011121548A1 (en) * | 2010-03-31 | 2011-10-06 | Ranbaxy Laboratories Limited | Process for the preparation of dexlansoprazole |
WO2012095859A1 (en) * | 2011-01-12 | 2012-07-19 | Hetero Research Foundation | Polymorphs of dexlansoprazole salts |
-
2016
- 2016-12-29 CN CN201611241574.3A patent/CN106619520B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101137371A (zh) * | 2005-01-14 | 2008-03-05 | 克卡制药新梅斯托股份公司 | 制备兰索拉唑的方法 |
CN101977909A (zh) * | 2008-03-18 | 2011-02-16 | 雷迪博士实验室有限公司 | 右兰索拉唑方法和多晶型物 |
CN102119927A (zh) * | 2010-01-11 | 2011-07-13 | 石药集团中奇制药技术(石家庄)有限公司 | 一种质子泵抑制剂的肠溶微丸制剂及其制备方法 |
CN103565770A (zh) * | 2012-07-31 | 2014-02-12 | 北京阜康仁生物制药科技有限公司 | 一种右兰索拉唑肠溶缓控释微丸片 |
Also Published As
Publication number | Publication date |
---|---|
CN106619520A (zh) | 2017-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101005716B1 (ko) | 3-[(2-{[4-(헥실옥시카보닐아미노-이미노-메틸)-페닐아미노]-메틸}-1-메틸-1h-벤즈이미다졸-5-카보닐)-피리딘-2-일-아미노] 프로피온산 에틸에스테르의 경구 투여 형태 | |
US6485743B1 (en) | Method and composition of an oral preparation of itraconazole | |
CN106619520B (zh) | 一种右兰索拉唑钠的干混悬剂及其制备方法 | |
JP5295123B2 (ja) | 新規医薬組成物 | |
TWI228414B (en) | Pharmaceutical composition comprising carvedilol and hydrochlorothiazide, solid dosage form comprising it, and process for the production of the same | |
JP2005526738A (ja) | 低溶解度の薬物を経口投与するための投与剤形 | |
JP2002523443A (ja) | オメプラゾール製剤 | |
CA2681465A1 (en) | Tablet formulations containing 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom | |
US9833436B2 (en) | Method of preparing drug agglomerate | |
CN103356489B (zh) | 一种质子泵抑制剂肠溶微丸及其制剂、制备方法 | |
US20060160871A1 (en) | Stable non-crystalline formulation comprising losartan | |
JP3967924B2 (ja) | 溶出性の改善されたプランルカスト固体分散系及びその製造方法 | |
US20170281586A1 (en) | Solid molecular dispersion of fesoterodine hydrogen fumarate and polymeric binder | |
CN104224754A (zh) | 一种达比加群酯药物组合物及其制备方法 | |
CN105919943A (zh) | 一种盐酸可乐定控释颗粒及其制备方法 | |
CN105764509B (zh) | 达比加群酯或其盐的投药制剂及其制备方法 | |
CN106727381A (zh) | 一种右兰索拉唑钠的口崩片及其制备方法 | |
WO2004066982A1 (en) | Stable oral benzimidazole compositions and processes for their preparation | |
CN113332256A (zh) | 一种达比加群酯微丸组合胶囊及其制备方法 | |
CN106668018B (zh) | 一种右兰索拉唑钠的缓释胶囊及其制备方法 | |
CN109806234A (zh) | 一种质子泵抑制剂肠溶片芯的制备方法 | |
CN105796517B (zh) | 一种盐酸多西环素肠溶片及其制备方法 | |
TWI606846B (zh) | 製備藥物凝集體的方法 | |
WO2015113324A1 (zh) | 达比加群酯及其盐的投药制剂及其制备方法 | |
WO2024088266A1 (zh) | 药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 210061 122, Hua Kang Road, hi tech Development Zone, Nanjing, Jiangsu. Applicant after: NANJING HAIRONG PHARMACEUTICAL CO., LTD. Applicant after: Chengdu Dikang pharmaceutical Limited by Share Ltd Address before: 210061 122, Hua Kang Road, hi tech Development Zone, Nanjing, Jiangsu. Applicant before: NANJING HAIRONG PHARMACEUTICAL CO., LTD. Applicant before: Chengdu Dikang Pharmaceutical Co., Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20170510 Assignee: Chongqing Dikang Changjiang Pharmaceutical Co.,Ltd. Assignor: NANJING HAIRONG PHARMACEUTICAL Co.,Ltd.|Chengdu Di Kang medicine companies LLC Contract record no.: X2021510000035 Denomination of invention: The invention relates to a dry suspension of right lansoprazole sodium and a preparation method thereof Granted publication date: 20190806 License type: Common License Record date: 20210916 |